These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28805099)

  • 1. Short-term daily teriparatide in patients with rheumatoid arthritis.
    Kaneko T; Okamura K; Yonemoto Y; Okura C; Suto T; Tachibana M; Tamura Y; Inoue M; Chikuda H
    Mod Rheumatol; 2018 May; 28(3):468-473. PubMed ID: 28805099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
    Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
    Nakatoh S
    J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.
    Ebina K; Hashimoto J; Shi K; Kashii M; Hirao M; Yoshikawa H
    Osteoporos Int; 2014 Dec; 25(12):2755-65. PubMed ID: 25082556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
    Ebina K; Noguchi T; Hirao M; Hashimoto J; Kaneshiro S; Yukioka M; Yoshikawa H
    Osteoporos Int; 2016 Jan; 27(1):351-9. PubMed ID: 26475289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
    J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
    Matsumoto T; Hagino H; Shiraki M; Fukunaga M; Nakano T; Takaoka K; Morii H; Ohashi Y; Nakamura T
    Osteoporos Int; 2009 Aug; 20(8):1429-37. PubMed ID: 19101754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
    Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
    Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur.
    Greenspan SL; Vujevich K; Britton C; Herradura A; Gruen G; Tarkin I; Siska P; Hamlin B; Perera S
    Osteoporos Int; 2018 Feb; 29(2):501-506. PubMed ID: 29085957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis.
    Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
    Calcif Tissue Int; 2017 Oct; 101(4):396-403. PubMed ID: 28589205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ; Tsai JN; Jiang LA; Lee H
    Bone; 2017 May; 98():54-58. PubMed ID: 28286299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.
    Okazaki R; Hagino H; Ito M; Sone T; Nakamura T; Mizunuma H; Fukunaga M; Shiraki M; Nishizawa Y; Ohashi Y; Matsumoto T
    Osteoporos Int; 2012 Jun; 23(6):1737-45. PubMed ID: 21932114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-Year Teriparatide Followed by Denosumab
    Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
    Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
    Mok J; Brown C; Moore AEB; Min SS; Hampson G
    Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.